



Novelion Therapeutics Inc.
Investor Relations Department
887 Great Northern Way, Suite 250
Vancouver V5T 4T5
Canada

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: NVLN

Last Trade:	10.18
Trade Time:	4:00 PM ET Jun 22, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	6.10 - 13.80
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jun 12, 2017*
[Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association](#)
- Jun 1, 2017*
[Novelion Therapeutics Appoints John J. Orloff, M.D., to Its Board of Directors, Steps Down as EVP, Head of R&D](#)
- May 9, 2017*
[Novelion Therapeutics Reports First Quarter 2017 Financial Results](#)
- May 5, 2017*
[Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology](#)
- May 3, 2017*
[Novelion Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017](#)

Financials [\[View all \]](#)

- Mar 30, 2017*
[Annual Report \(10-K\)](#)
- May 1, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*
[Quarterly Report \(10-Q\)](#)
- Nov 1, 2016*
[Quarterly Report \(10-Q\)](#)